- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright bestätigt Kaufempfehlung für Medicenna mit Kursziel von 2,50 $ | - | Investing.com Deutsch | ||
| Mo | H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target | 1 | Investing.com | ||
| Mo | H.C. Wainwright reiterates Buy rating on Medicenna stock with $2.50 target | 1 | Investing.com | ||
| Fr | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Medicenna Therapeutics Corp. Q1 Loss Rises | 1 | RTTNews | ||
| Fr | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 83 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
| Do | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 26.06. | Medicenna Therapeutics GAAP EPS of -C$0.15 | 3 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 284 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen | |
| 01.05. | Medicenna Therapeutics Corp: Medicenna presents preclinical MDNA113 data at meeting | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics Corp: Medicenna's MDNA11 showing acceptable safety profile | 1 | Stockwatch | ||
| 29.04. | Medicenna Therapeutics has "elegant science", Research Capital says | 2 | Cantech Letter | ||
| 22.04. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 26.03. | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
| 26.03. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 25.02. | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study data | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 169 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
| 05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 178 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
| 15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 212 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
| 11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 180 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,820 | -3,28 % | Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben | DJ Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben
DOW JONES--Qiagen hat mit den Ergebnissen für das zweite Quartal die Erwartungen übertroffen und den Ausblick für das... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,540 | +16,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| BIONTECH | 94,80 | -1,25 % | Trumps Zölle & Übernahmen! BioNTech, PanGenomic Health, Pfizer und Valneva im Visier der Spekulanten | Nun ist die USA-EU-Zollbeziehung beschlossen. Für viele Sektoren der Wirtschaft kommt es in Europa nun zu Sonderbelastungen und Margeneinschnitten. Verschont bleibt die BioTech- und Pharmabranche, denn... ► Artikel lesen | |
| EVOTEC | 6,502 | -2,96 % | Evotec und Sandoz zünden Biologika-Bombe: 300 Mio. USD-Deal für J.POD-Anlage in Toulouse! | Evotec SE (ISIN: DE0005664809) hat heute den Abschluss einer nicht-bindenden Vereinbarung mit Sandoz AG (SIX: SDZ) über den möglichen Verkauf ihrer J.POD-Biologika-Fertigungsplattform in Toulouse bekannt... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,505 | -0,06 % | Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition | ||
| DYNE THERAPEUTICS | 11,720 | +11,94 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AINOS | 3,590 | +56,09 % | Ainos, Inc.: Ainos Secures $2.1 Million Order With ASE Technology for First Deployment of AI Nose in Semiconductor Manufacturing Setting | First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial ApplicationsAinos Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan SAN... ► Artikel lesen | |
| NOVAVAX | 6,514 | +11,75 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 5,800 | -15,64 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
| VERA THERAPEUTICS | 19,640 | -4,84 % | Vera Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| AMGEN | 244,00 | -5,99 % | Prognose-Schock vs. Prognose-Boost - Zalando, Fresenius, Beiersdorf, Qiagen, Super Micro, AMD, Amgen | Der DAX hat sich gestern erneut gut geschlagen und an die starke Performance vom Montag angeknüpft. Es gab zwar die eine oder andere Schwächephase. Trotzdem schloss der DAX 0,37 Prozent höher bei 23.846... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,395 | -2,18 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| MODERNA | 22,975 | -3,24 % | Ihre wichtigsten Termine: Alle Blicke auf: Moderna, Chevron, Daimler Truck, Snap und Colgate-Palmolive | © Foto: Rishi Deka/ZUMA Press Wire/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 28,550 | -1,91 % | Summit Therapeutics: Ivonescimab zeigt überlegenes progressionsfreies Überleben gegenüber Pembrolizumab | ||
| HARMONY BIOSCIENCES | 34,160 | -2,20 % | Harmony Biosciences: Aktie fällt trotz Gewinnplus nach verfehlten Umsatzerwartungen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.